Not necessarily, it depends on what the patient is being treated for. Any of the rare diseases come into play. Not to mention that DMD affects upwards of 6,000 people, provides ample revenue without even considering off label use.
.. my last message seems to have disappeared, so I'll repost and apologize in advance for any duplication. A thoughtful article that appeared in Biocentury (week of Feb 4th) by Stephen Hansen, titled "Head to head in hoFH", and it makes the point that there are roughtly 300 hoFH patients in the US.
Using the assumption of 300 patients, adjusting for the dropout rate seen on the trial (i believe about 14% discontinued for GI issues), and also adjusting for competition from Kynamro, what does that do to the valuation $$/share?